전립선 절제 기기 시장 규모, 점유율 및 동향 분석 보고서 : 제품 및 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Prostatic Ablation Devices Market Summary

The global prostatic ablation devices market size was valued at USD 2.2 billion in 2025 and is projected to grow from USD 2.5 billion in 2026 to USD 6.3 billion by 2033, at a CAGR of 14.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 46.4% in 2025. The growth of the prostatic ablation devices industry is primarily driven by the rising prevalence of localized prostate cancer and benign prostatic hyperplasia (BPH), coupled with increasing demand for minimally invasive treatment options that reduce hospital stays and preserve urinary and sexual function.

The growth of the prostatic ablation devices industry is primarily driven by the rising prevalence of localized prostate cancer and benign prostatic hyperplasia (BPH), coupled with increasing demand for minimally invasive treatment options that reduce hospital stays and preserve urinary and sexual function. In addition, continuous advancements in image-guided ablation technologies, including focal therapies such as laser ablation, ultrasound ablation, cryotherapy, and irreversible electroporation, are improving treatment precision and accelerating clinical adoption.

The rising prevalence of benign prostatic hyperplasia (BPH) and prostate cancer is a major driver of the market. The growing elderly male population and increasing awareness of prostate health are leading to higher diagnosis and treatment rates worldwide. As more patients seek minimally invasive alternatives that offer faster recovery, fewer complications, and preservation of urinary and sexual function, the demand for advanced prostate ablation devices continues to grow across both BPH and localized prostate cancer indications.

Furthermore, continuous advancements in image-guided ablation technologies are driving growth in the prostate ablation device market by improving procedural precision, treatment planning, and clinical outcomes. The integration of multiparametric MRI (mpMRI), real-time ultrasound, MRI-ultrasound fusion imaging, and robotic navigation enables accurate localization and targeted ablation of prostate lesions while minimizing damage to surrounding healthy tissue. These innovations enhance physician confidence, reduce procedure-related complications, and improve preservation of urinary continence and sexual function.

The development of MRI-guided transurethral ultrasound ablation (TULSA), advanced high-intensity focused ultrasound (HIFU) systems, and image-guided irreversible electroporation (IRE) platforms has expanded treatment options for both benign prostatic hyperplasia (BPH) and localized prostate cancer. Continuous improvements in software, treatment planning algorithms, and real-time monitoring capabilities are expected to support wider clinical adoption and drive sustained demand for advanced prostate ablation devices.

• For instance, in April 2026, Profound Medical announced that its TULSA-PRO platform would be featured in multiple presentations at the Society of Interventional Radiology Annual Scientific Meeting 2026. The system combines real-time MRI guidance with directional ultrasound to enable incision-free, personalized prostate ablation with continuous treatment monitoring and verification.

"Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed," said Arun Menawat, Profound's CEO and Chairman. "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing. And we look forward to building on that progress by highlighting CAPTAIN trial data and showcasing real-world physician experience throughout 2026."

Moreover, the expanding use of focal therapy for localized prostate cancer presents a significant growth opportunity for the prostate ablation device market. Advances in multiparametric MRI, targeted biopsy, and image-guided ablation technologies are improving treatment precision while preserving healthy prostate tissue and reducing treatment-related side effects. As clinical evidence supporting focal therapy continues to grow and more patients seek organ-preserving, minimally invasive treatment options, the demand for advanced prostate ablation devices is expected to increase across hospitals and specialized urology centers.

Global Prostatic Ablation Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global prostatic ablation devices market report based on product /technology, application, end use, and region:

• Product / Technology Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Radiofrequency (RF) Ablation Device
• High-Intensity Focused Ultrasound (HIFU) Devices
• Cryoablation Devices
• Microwave Ablation (MWA) / Thermotherapy Devices
• Water Vapor Ablation System
• Laser System
• Irreversible Electroporation (IRE)
• Application Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Benign Prostatic Hyperplasia (BPH)
• Prostate Cancer
• Others
• End Use Outlook (Revenue, USD Million/Billion; 2021 - 2033)
• Hospitals
• Ambulatory Surgery Centers
• Specialty Urology Clinics
• Cancer Centers
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product / Technology
  • 1.1.2. Application
  • 1.1.3. End Use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Prostatic Ablation Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Pipeline Analysis
  • 3.2.1. Innovation trends and approvals
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
    • 3.3.1.1. Increasing burden of benign prostatic hyperplasia (bph) and prostate cancer
    • 3.3.1.2. Shift toward minimally invasive and organ-preserving treatments
    • 3.3.1.3. Advancements in image-guided ablation technologies
    • 3.3.1.4. Increasing preference for outpatient and ambulatory procedures
  • 3.3.2. Market restraint analysis
    • 3.3.2.1. High capital investment and procedure costs
    • 3.3.2.2. Limited long-term clinical evidence for some emerging technologies
  • 3.3.3. Market opportunity analysis
    • 3.3.3.1. Expansion of focal therapy for localized prostate cancer
    • 3.3.3.2. Integration of artificial intelligence with image-guided ablation systems
    • 3.3.3.3. Growing demand in emerging healthcare markets
    • 3.3.3.4. Development of next-generation energy modalities and combination therapies
  • 3.3.4. Market challenge analysis
    • 3.3.4.1. Lack of standardized clinical guidelines and long-term evidence
    • 3.3.4.2. Difficulty in patient selection and treatment planning
• 3.4. Prostatic Ablation Devices Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Bargaining power of suppliers
    • 3.4.1.2. Bargaining power of buyers
    • 3.4.1.3. Threat of substitutes
    • 3.4.1.4. Threat of new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political & Legal Landscape
    • 3.4.2.2. Economic and Social Landscape
    • 3.4.2.3. Technological landscape

Chapter 4. Prostatic Ablation Devices Market: Product / Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Prostatic Ablation Devices Market Product / Technology Movement Analysis
• 4.3. Global Prostatic Ablation Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million/Billion)
• 4.4. Radiofrequency (RF) Ablation Device
  • 4.4.1. Radiofrequency (RF) ablation device market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 4.5. High-Intensity Focused Ultrasound (HIFU) Devices
  • 4.5.1. High-intensity focused ultrasound (HIFU) devices market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 4.6. Cryoablation Devices
  • 4.6.1. Cryoablation devices market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 4.7. Microwave Ablation (MWA) / Thermotherapy Devices
  • 4.7.1. Microwave ablation (MWA) / thermotherapy devices market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 4.8. Water Vapor Ablation System
  • 4.8.1. Water vapor ablation system market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 4.9. Laser System
  • 4.9.1. Laser system market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 4.10. Irreversible Electroporation (IRE)
  • 4.10.1. Irreversible electroporation (IRE) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 5. Prostatic Ablation Devices Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Prostatic Ablation Devices Market Application Movement Analysis
• 5.3. Global Prostatic Ablation Devices Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million/Billion)
• 5.4. Benign Prostatic Hyperplasia (BPH)
  • 5.4.1. Benign prostatic hyperplasia (BPH) market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 5.5. Prostate Cancer
  • 5.5.1. Prostate cancer market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 6. Prostatic Ablation Devices Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Prostatic Ablation Devices Market End Use Movement Analysis
• 6.3. Global Prostatic Ablation Devices Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million/Billion)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory surgical centers market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 6.6. Specialty Urology Clinics
  • 6.6.1. Specialty urology clinics market estimates and forecasts for 2021 to 2033 (USD Million/Billion)
• 6.7. Cancer Centers
  • 6.7.1. Cancer centers market estimates and forecasts for 2021 to 2033 (USD Million/Billion)

Chapter 7. Prostatic Ablation Devices Market: Regional Estimates & Trend Analysis by Product / Technology, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million/Billion)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Competitive scenario
    • 7.4.1.3. Regulatory framework
    • 7.4.1.4. Reimbursement scenario
    • 7.4.1.5. UK market estimates and forecasts, 2021 - 2033
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. Germany market estimates and forecasts, 2021 - 2033
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. France market estimates and forecasts, 2021 - 2033
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 7.4.6. Denmark
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Norway market estimates and forecasts, 2021 - 2033
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement scenario
    • 7.5.1.5. Japan market estimates and forecasts, 2021 - 2033
  • 7.5.2. India
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. India market estimates and forecasts, 2021 - 2033
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. China market estimates and forecasts, 2021 - 2033
  • 7.5.4. South Korea
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. Australia market estimates and forecasts, 2021 - 2033
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement scenario
    • 7.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Boston Scientific Corporation
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. PROCEPT BioRobotics Corporation
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Urologix, LLC.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. EDAP TMS
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Sonablate Corp.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Insightec
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Profound Medical Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. ProVerum Ltd.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Francis Medical, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. AngioDynamics
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Mermaid Medical
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. IceCure Medical
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
• 8.4. Estimated Company Market Share Analysis, 2025
• 8.5. List of Other Key Market Players